HR and breast cancer: In both the neoadjuvant (Table 3) and adjuvant (Table 4) settings, and across stages I–III, physicians reported using doxorubicin in combination with cyclophosphamide (AC) with or without a taxane in more than 40% of their HR+/HER2(−) breast cancer patients.